Effect of renal impairment on the pharmacokinetics of bupropion and its metabolites

British Journal of Clinical Pharmacology

Volumn 64, Issue 2, 2007, Pages 165-173

  Turpeinen, Miia ^a   Koivuviita, Niina ^b   Tolonen, Ari ^c   Reponen, Petri ^a   Lundgren, Stefan ^d   Miettunen, Jouko ^a   Metsärinne, Kaj ^b   Rane, Anders ^d   Pelkonen, Olavi ^a   Laine, Kari ^e  

^a UNIVERSITY OF OULU   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c Novamass Analytical Ltd   (Finland)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY OF TURKU   (Finland)

Author keywords

Bupropion; Cytochrome P450; Pharmacokinetics; Renal failure

Indexed keywords

AMFEBUTAMONE; CYTOCHROME P450 2B6; DRUG METABOLITE; HYDROXYBUPROPION; UNCLASSIFIED DRUG;

ADULT; AMINO ACID SUBSTITUTION; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EFFECT; DRUG ELIMINATION; DRUG EXCRETION; DRUG HYDROXYLATION; ENZYME ACTIVITY; FEMALE; GENOTYPE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; PRIORITY JOURNAL; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; SUSTAINED RELEASE FORMULATION;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUPROPION; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENOTYPE; HUMANS; KIDNEY DISEASES; MALE; TREATMENT OUTCOME;

EID: 34447322601     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2007.02866.x     Document Type: Article

References (28)

1. Holm KJ, Spencer CM. Bupropion: a review of its use in the management of smoking cessation. Drugs 2000 59 : 1007 24.
2. Jefferson JW, Pradko JF, Muir KT. Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations. Clin Ther 2005 27 : 1685 95.
3. Hesse LM, Venkatakrishnan K, Court MH, von Moltke LL, Duan SX, Shader RI, Greenblatt DJ. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 2000 28 : 1176 83.
4. Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, Laethem RM, Lindley CM. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 2000 28 : 1222 30.
5. Borges V, Yang E, Dunn J, Henion J. High-throughput liquid chromatography-tandem mass spectrometry determination of bupropion and its metabolites in human, mouse and rat plasma using a monolithic column. J Chromatogr B Anal Technol Biomed Life Sci 2004 804 : 277 87.
6. Turpeinen M, Tolonen A, Uusitalo J, Jalonen J, Pelkonen O, Laine K. Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin Pharmacol Ther 2005 77 : 553 9.
7. Xie HJ, Yasar U, Lundgren S, Griskevicius L, Terelius Y, Hassan M, Rane A. Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J 2003 3 : 53 61.
8. Kirchheiner J, Klein C, Meineke I, Sasse J, Zanger UM, Murdter TE, Roots I, Brockmoller J. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics 2003 13 : 619 26.
9. Nolin TD, Frye RF, Matzke GR. Hepatic drug metabolism and transport in patients with kidney disease. Am J Kidney Dis 2003 42 : 906 25.
10. Dreisbach AW, Japa S, Gebrekal AB, Mowry SE, Lertora JJ, Kamath BL, Rettie AE. Cytochrome P4502C9 activity in end-stage renal disease. Clin Pharmacol Ther 2003 73 : 475 7.
11. Dowling TC, Briglia AE, Fink JC, Hanes DS, Light PD, Stackiewicz L, Karyekar CS, Eddington ND, Weir MR, Henrich WL. Characterization of hepatic cytochrome P4503A activity in patients with end-stage renal disease. Clin Pharmacol Ther 2003 73 : 427 34.
12. Heinonen EH, Anttila MI, Lammintausta RA. Pharmacokinetic aspects of 1-deprenyl (selegiline) and its metabolites. Clin Pharmacol Ther 1994 56 : 742 9.
13. Hidestrand M, Oscarson M, Salonen JS, Nyman L, Pelkonen O, Turpeinen M, Ingelman-Sundberg M. CYP2B6 CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes. Drug Metab Dispos 2001 29 : 1480 4.
14. Anttila M, Sotaniemi EA, Pelkonen O, Rautio A. Marked effect of liver and kidney function on the pharmacokinetics of selegiline. Clin Pharmacol Ther 2005 77 : 54 62.
15. Storrow AB. Bupropion overdose and seizure. Am J Emerg Med 1994 12 : 183 4.
16. Davidson J. Seizures and bupropion: a review. J Clin Psychiatry 1989 50 : 256 61.
17. Worrall SP, Almond MK, Dhillon S. Pharmacokinetics of bupropion and its metabolites in haemodialysis patients who smoke. A single dose study. Nephron Clin Pract 2004 97 : 83 9.
18. Turpeinen M. Raunio, Pelkonen O. The functional role of CYP2B6 in human drug metabolism: substrates and inhibitors in vitro, in vivo and in silico. Curr Drug Metab 2006 7 : 705 14.
19. Loboz KK, Gross AS, Williams KM, Liauw WS, Day RO, Blievernicht JK, Zanger UM, McLachlan AJ. Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. Clin Pharmacol Ther 2006 80 : 75 84.
20. Palovaara S, Pelkonen O, Uusitalo J, Lundgren S, Laine K. Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation. Clin Pharmacol Ther 2003 74 : 326 33.
21. DeVane CL, Laizure SC, Stewart JT, Kolts BE, Ryerson EG, Miller RL, Lai AA. Disposition of bupropion in healthy volunteers and subjects with alcoholic liver disease. J Clin Psychopharmacol 1990 10 : 328 32.
22. Kaka JS, Al-Khamis KI, Tanira MO. Effect of hepatic and renal dysfunction on disposition of bupropion in rats. Eur J Drug Metab Pharmacokinet 1988 13 : 149 53.
23. Findlay JW, Van Wyck Fleet J, Smith PG, Butz RF, Hinton ML, Blum MR, Schroeder DH. Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects. Eur J Clin Pharmacol 1981 21 : 127 35.
24. Sweet RA, Pollock BG, Kirshner M, Wright B, Altieri LP, DeVane CL. Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression. J Clin Pharmacol 1995 35 : 876 84.
25. Dreisbach AW, Lertora JJ. The effect of chronic renal failure on hepatic drug metabolism and drug disposition. Semin Dial 2003 16 : 45 50.
26. Elston AC, Bayliss MK, Park GR. Effect of renal failure on drug metabolism by the liver. Br J Anaesth 1993 71 : 282 90.
27. Rostami-Hodjegan A, Kroemer HK, Tucker GT. In vivo indices of enzyme activity. the effect of renal impairment on the assessment of CYP2D6 activity. Pharmacogenetics 1999 9 : 277 86.
28. Nolin TD, Gastonguay MR, Bies RR, Matzke GR, Frye RF. Impaired 6-hydroxychlorzoxazone elimination in patients with kidney disease: Implication for cytochrome P450 2E1 pharmacogenetic studies. Clin Pharmacol Ther 2003 74 : 555 68.